SAN DIEGO, June 25, 2018 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted
oncology company, today announced that it has been added to the
Russell 2000® Index, effective as of the open of the
market on Monday, June 25, 2018,
following Russell's annual reconstitution of its comprehensive set
of U.S. and global equity indexes.
The Russell 2000® Index measures the performance of
the small-cap segment of the U.S. equity market. The index is a
subset of the Russell 3000® Index and represents
approximately 10 percent of the total market capitalization of that
index.
Russell US indexes are widely used by investment managers and
institutional investors as the basis for index funds and as
benchmarks for active investment strategies. Approximately
$9 trillion in assets are benchmarked
against the Russell Indexes. Russell US Indexes are part of FTSE
Russell, a leading global index provider. For more information on
the Russell 2000® Index and the Russell indexes
reconstitution, go to the "Russell Reconstitution" section on the
FTSE Russell website.
About Mirati
Mirati Therapeutics, Inc. is a clinical-stage oncology company
developing targeted product candidates to address the genetic,
epigenetic and immunological promoters of cancer. Our precision
oncology clinical programs utilize next-generation genomic testing
to identify and select cancer patients who are most likely to
benefit from targeted drug treatment. In immuno-oncology, we are
advancing clinical programs where the ability of our product
candidates to improve the immune environment of tumor cells may
enhance and expand the efficacy of existing immunotherapy medicines
when given in combination. Our pre-clinical programs include
potentially first-in-class and best-in-class product candidates
specifically designed to address mutations and tumors where few
treatment options exist. We approach each of our discovery and
development programs with a singular focus: to translate our deep
understanding of the molecular drivers of cancer into better
therapies and better outcomes for patients. For more information,
visit www.mirati.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release regarding the business
of Mirati Therapeutics, Inc. ("Mirati") that are not historical
facts may be considered "forward-looking statements," including
without limitation statements regarding Mirati's development plans
and timelines, potential regulatory actions, expected use of cash
resources, the timing and results of clinical trials, and the
potential benefits of and markets for Mirati's product candidates.
Forward-looking statements are typically, but not always,
identified by the use of words such as "may," "will," "would,"
"believe," "intend," "plan," "anticipate," "estimate," "expect,"
and other similar terminology indicating future results.
Forward-looking statements are based on current expectations of
management and on what management believes to be reasonable
assumptions based on information currently available to them and
are subject to risks and uncertainties. Such risks and
uncertainties may cause actual results to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include without limitation potential delays in
development timelines, negative clinical trial results, reliance on
third parties for development efforts, changes in the competitive
landscape, changes in the standard of care, as well as other risks
detailed in Mirati's recent filings on Forms 10-K and 10-Q with the
U.S. Securities and Exchange Commission. Except as required by law,
Mirati undertakes no obligation to update any forward-looking
statements to reflect new information, events or circumstances, or
to reflect the occurrence of unanticipated events.
View original content with
multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-added-to-russell-2000-index-300671869.html
SOURCE Mirati Therapeutics, Inc.